AzTrials
AzTrials

Safety IssuesNCT06448442

A Pilot Study of Deep Cervical Lymphatic-venous Anastomosis in the Treatment of Alzheimer's Disease

An observational study of Safety Issues and Feasibility, run by Second Affiliated Hospital, Zhejiang University, School of Medicine.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

Alzheimer's disease (AD) is the most prevalent form of dementia, affecting 3-4% of the population over a lifetime. It's characterized by abnormal Amyloid-beta (Aβ) and tau protein expression and accumulation in the central nervous system, leading to amyloid plaques and neurofibrillary tangles. Read more about this study

Who is it for?
Ages 50 to 90 yearsHealthy volunteers can take part
Conditions the study is for
Safety Issues, Feasibility, Therapeutic Value
How many people
8 participants
Where
No sites listed yet
Study dates
1 Aug 2024to 1 Aug 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients with Alzheimer's disease

Who may be able to join

  • a. aged 50-90 years (> or equal to 50 years old, < or equal to 90 years old) were evaluated as Alzheimer's disease group according to the 2018 NIA-AA diagnostic criteria; B. signed by the patient or family informed consent; c. Patients with mild or moderate disease, 11≤MMSE≤26; d. Subjects with primary school education or above can complete the prescribed scale evaluation; The diagnosis of AD was confirmed by e.PET or cerebrospinal fluid examination

Who cannot join

  • a. any other disease that can cause cognitive impairment (e.g., dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease dementia, etc.), intracranial mass impairing cognition, history of traumatic brain injury, normal pressure hydrocephalus, history of clinically significant cerebrovascular disease; b. Excluding other diseases affecting the nervous system, including nervous system infection, epilepsy, and systemic diseases affecting the function of the nervous system; c. Inability to cooperate with cognitive testing; d. Presence of contraindications to MRI examination (e.g., pacemakers, stents, claustrophobia, severe psychiatric symptoms, etc.).

About this study

Alzheimer's disease (AD) is the most prevalent form of dementia, affecting 3-4% of the population over a lifetime. It's characterized by abnormal Amyloid-beta (Aβ) and tau protein expression and accumulation in the central nervous system, leading to amyloid plaques and neurofibrillary tangles. While current treatments can slow cognitive decline, there's no cure.

The discovery of the "glymphatic-meningeal lymphatic" system has shed new light on cerebrospinal fluid circulation, showing it has a similar interstitial fluid system to peripheral lymphatic circulation. This system helps clear waste and transport nutrients in the brain, known as the glymphatic phenomenon. The deep cervical lymph nodes, part of this system, are crucial for cerebrospinal fluid drainage and are linked to the clearance of AD-related proteins.

Aging and inflammation can impair deep cervical lymph node function, increasing cerebrospinal fluid drainage pressure and potentially contributing to AD progression. Lymphatic anastomosis, a surgical technique used for lymphedema and other conditions, is being explored as a potential treatment to alleviate neurodegenerative disease by reducing cerebrospinal fluid pressure and clearing metabolic waste.

Read the detailed description

Alzheimer's disease (AD) is the most common form of dementia, with an estimated lifetime prevalence rate of 3-4%. Its characteristics include abnormal expression of Amyloid-beta (Aβ) and tau proteins, as well as their accumulation in the central nervous system. The aggregated toxic proteins further form amyloid plaques and neurofibrillary tangles. One of the biggest scientific and therapeutic challenges of AD is to elucidate this protein pathology and how it leads to accumulation in the central nervous system. Although current drug treatment options can slow down the decline in cognitive abilities, there is no treatment strategy to improve the disease.

Recently, the revelation of the "glymphatic-meningeal lymphatic" system has updated the latest theory of cerebrospinal fluid circulation. There is an interstitial fluid circulation system in the brain tissue that is similar to peripheral lymphatic circulation. Research has found that cerebrospinal fluid in the brain enters the perivascular space around the veins through the perivascular space around the arteries, directed by the astrocyte Aquaporin protein-4, which promotes the clearance of waste and the transport of nutrients in the brain, a phenomenon known as the glymphatic phenomenon. At the same time, research has found that there are a large number of lymphatic vessels on both sides of the dural venous sinuses, which participate in the drainage of cerebrospinal fluid and eventually converge into the deep cervical lymph nodes. In animal models of AD and Parkinson's disease (PD), the "glymphatic-meningeal lymphatic" drainage function is significantly related to the clearance of disease-related proteins such as amyloid beta (Aβ), tau, and alpha-synuclein. Ligation of the deep cervical lymph nodes significantly exacerbates the progression of the disease. At the same time, clinical studies have confirmed the decline of "glymphatic-meningeal lymphatic" function in patients with AD and PD through magnetic resonance imaging technology.

The deep cervical lymph nodes play an important role as the final destination of cerebrospinal fluid drainage in the "glymphatic-cranial lymphatic" system. With aging, infection, and chronic inflammation, the function of the deep cervical lymph nodes gradually declines, which will significantly increase the pressure of cerebrospinal fluid circulation and reflux in the brain. The large amount of neurotoxic substances produced during the progression of AD, will further lead to the dysfunction of the deep cervical lymph nodes, ultimately leading to abnormal accumulation of toxic substances in the brain and the progression of the disease. Lymphatic anastomosis is a surgical technique widely used for limb lymphedema, post-traumatic chylous chest, breast cancer, and other post-tumor resection local edema and other diseases, with high safety, reliability, and ease of operation, and has been proven to have many advantages after half a century of testing. Currently, many hospitals at home and abroad have carried out related operations, all of which have achieved good results. Recently, only in our province, Zhejiang Provincial People's Hospital, Taizhou Hospital, Hangzhou Qiushi Hospital, and others have carried out related operations, and the famous Cleveland Clinic in the United States is also conducting related surgical treatment research.

We speculate that anastomosing the corresponding lymphatic vessels in the neck with the veins (Deep Cervical Lymph-Venous anastomosis) might reduce the cerebrospinal fluid circulation pressure in the brain tissue, accelerate the return of interstitial fluid in the brain tissue, clear the accumulation of metabolic products, and alleviate the progression of neurodegenerative diseases.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Alzheimer's Disease Assessment scale

    ADAS-cog14; range 0 to 90

    Measured: 1 week pre-suregery and 1 week, 1 month and 3 month after suregery

Secondary outcomes (2)
  1. Alzheimer's Disease Composite Score

    ADCOMS; range 0 to 1.97

    Measured: 1 week pre-suregery and 1 week, 1 month and 3 month after suregery

  2. Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment

    Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment. ADCS-MCI-ADL; range, 0 to 53

    Measured: 1 week pre-suregery and 1 week, 1 month and 3 month after suregery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jun 2024
  2. Study start1 Aug 2024 (estimated)
  3. Primary completion1 Aug 2027 (estimated)
  4. Study completion1 Aug 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case crossover
Time perspective
Prospective
Enrolment
8 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06448442
Sponsor's protocol ID
2024-0429
Status last verified
Jun 2024
First submitted
3 Jun 2024
Last updated
7 Jun 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Safety Issues and Feasibility, run by Second Affiliated Hospital, Zhejiang University, School of Medicine.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 7 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Alzheimer's Disease Assessment scale (time frame: 1 week pre-suregery and 1 week, 1 month and 3 month after suregery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in